HLS Therapeutics Inc (TSE:HLS) has released an update.
HLS Therapeutics Inc. is set to announce its second-quarter financial results for fiscal year 2024 on August 8, with a conference call scheduled for that morning hosted by CEO Craig Millian and Interim CFO John Hanna. The company specializes in acquiring and commercializing pharmaceuticals in North America, focusing on treatments for psychiatric disorders and cardiovascular disease.
For further insights into TSE:HLS stock, check out TipRanks’ Stock Analysis page.
